NEORTESBIO
Neortesbio is an innovative biotech company dedicated to developing next-generation biotherapeutics that surpass current limitations. Focused on diseases with high unmet clinical needs such as solid tumors, autoimmune disorders, and ocular diseases, the company combines novel biology with industry-leading technologies to create pipelines of therapeutics aimed at improving patient lives and contributing to society.
Industries
Nr. of Employees
small (1-50)
NEORTESBIO
#305, 331 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea
Products
Monoclonal antibody-based vessel normalization therapeutic candidate
Preclinical therapeutic candidate that targets pathogenic antagonists to normalize abnormal/leaky blood vessels, intended to improve tissue blood flow and enhance delivery and efficacy of co-administered therapies for ocular and oncology indications.
Antibody discovery and engineering platform
Internal platform capabilities for antibody discovery and engineering including bispecific constructs, ADC portfolio development, high-expression technology, and structure-based optimization.
Monoclonal antibody-based vessel normalization therapeutic candidate
Preclinical therapeutic candidate that targets pathogenic antagonists to normalize abnormal/leaky blood vessels, intended to improve tissue blood flow and enhance delivery and efficacy of co-administered therapies for ocular and oncology indications.
Antibody discovery and engineering platform
Internal platform capabilities for antibody discovery and engineering including bispecific constructs, ADC portfolio development, high-expression technology, and structure-based optimization.
Services
Management and coordination of external contract research and manufacturing partners to support preclinical, CMC and clinical development activities.
Management and coordination of external contract research and manufacturing partners to support preclinical, CMC and clinical development activities.
Expertise Areas
- Antibody therapeutic development
- Vessel normalization therapeutics
- Ocular disease therapeutics (wet AMD, diabetic retinopathy)
- Oncology — solid tumors
Key Technologies
- Monoclonal antibodies
- Bispecific / dual-antibody platforms
- Antibody-drug conjugates (ADC)
- Structure-based protein engineering